

2022-2023 ECCO Annual Disclosure of Potential Conflict of Interest

Name: Zeissig, Sebastian

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'23 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'23 presentations, the 2022-2023 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
 - I have no potential conflict of interest to disclose
 - I have potential conflict of interest to disclose

- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
 - Grant
 - Personal Fees
 - Non-financial support
 - Other

Disclosures statement based on answers received:

Personal Fees:|Advisory: Abbvie Deutschland GmbH, Amgen GmbH, Biogen GmbH, Bristol-Myers Squibb GmbH, Celltrion Healthcare, Ferring Arzneimittel GmbH, Hogg Robinson GmbH, Mylan, Janssen Cilag GmbH, Pfizer Pharma GmbH, Takeda Pharma GmbH. Speakers bureau: Abbvie Deutschland GmbH, Amgen GmbH, Biogen GmbH, Bristol-Myers Squibb GmbH, CED Service GmbH, Falk Foundation e.V., Ferring Arzneimittel GmbH, FORGA Solutions GmbH, GWT-TUD GmbH, Janssen Cilag GmbH, Janssen Pharmaceutica NV, MSD Sharp & Dome, Roche, Pfizer Pharma GmbH, Pharma Zentrale GmbH, Takeda Pharma GmbH, WebMD Global